dc.contributor.author |
Khati, M
|
|
dc.date.accessioned |
2010-11-08T13:07:42Z |
|
dc.date.available |
2010-11-08T13:07:42Z |
|
dc.date.issued |
2010-06 |
|
dc.identifier.citation |
Khati, M. 2010. Future of aptamers in medicine. Journal of Clinical Pathology, Vol.63(6), pp 480-487 |
en |
dc.identifier.uri |
jcp.bmj.com
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/4542
|
|
dc.description |
Copyright: 2010 BMJ Publishing Group |
en |
dc.description.abstract |
Aptamers, simply described as chemical antibodies, are synthetic oligonucleotide ligands or peptides that can be isolated in vitro against diverse targets including toxins, bacterial and viral proteins, virus infected cells, cancer cells and whole pathogenic microorganisms. Aptamers assume a defined three-dimensional structure and generally bind functional sites on their respective targets. They possess the molecular recognition properties of monoclonal antibodies in terms of their high affinity and specificity. The applications of aptamers range from diagnostics and biosensing, target validation, targeted drug delivery, therapeutics, templates for rational drug design to biochemical screening of small molecule leads compounds. The review describes recent progress made in the application of biomedically relevant aptamers and relate them to their future clinical prospects. |
en |
dc.language.iso |
en |
en |
dc.publisher |
BMJ Publishing Group |
en |
dc.relation.ispartofseries |
Journal Article |
en |
dc.subject |
Aptamers |
en |
dc.subject |
Oligonucleotide ligands |
en |
dc.subject |
Clinical prospects |
en |
dc.subject |
Peptides |
en |
dc.subject |
Monoclonal antibodies |
en |
dc.title |
Future of aptamers in medicine |
en |
dc.type |
Article |
en |
dc.identifier.apacitation |
Khati, M. (2010). Future of aptamers in medicine. http://hdl.handle.net/10204/4542 |
en_ZA |
dc.identifier.chicagocitation |
Khati, M "Future of aptamers in medicine." (2010) http://hdl.handle.net/10204/4542 |
en_ZA |
dc.identifier.vancouvercitation |
Khati M. Future of aptamers in medicine. 2010; http://hdl.handle.net/10204/4542. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Khati, M
AB - Aptamers, simply described as chemical antibodies, are synthetic oligonucleotide ligands or peptides that can be isolated in vitro against diverse targets including toxins, bacterial and viral proteins, virus infected cells, cancer cells and whole pathogenic microorganisms. Aptamers assume a defined three-dimensional structure and generally bind functional sites on their respective targets. They possess the molecular recognition properties of monoclonal antibodies in terms of their high affinity and specificity. The applications of aptamers range from diagnostics and biosensing, target validation, targeted drug delivery, therapeutics, templates for rational drug design to biochemical screening of small molecule leads compounds. The review describes recent progress made in the application of biomedically relevant aptamers and relate them to their future clinical prospects.
DA - 2010-06
DB - ResearchSpace
DP - CSIR
KW - Aptamers
KW - Oligonucleotide ligands
KW - Clinical prospects
KW - Peptides
KW - Monoclonal antibodies
LK - https://researchspace.csir.co.za
PY - 2010
T1 - Future of aptamers in medicine
TI - Future of aptamers in medicine
UR - http://hdl.handle.net/10204/4542
ER -
|
en_ZA |